Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Kramer

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
The British Journal of Ophthalmology|July 11, 2025
Adalimumab biosimilars have similar efficacy to originator adalimumab when treating non-infectious uveitisOren Tomkins-Netzer, Rachael L Niederer, Radgonde Amer, et al.
Acta Ophthalmologica|March 6, 2018
Cat-scratch disease: ocular manifestations and treatment outcomeZohar Habot-Wilner, Omer Trivizki, Michaella Goldstein, et al.
American Journal of Ophthalmology|October 18, 2025
AI-Driven Optical Coherence Tomography Biomarkers for Choroidal Neovascularization Assessment in Punctate Inner Choroidopathy and Multifocal ChoroiditisLorenzo Ferro Desideri, Mathias Gallardo, Muriel Ott, et al.
Acta Ophthalmologica|February 8, 2023
Retinal vascular occlusions in ocular Behçet disease - a comparative analysisMichael Ostrovsky, Dan Ramon, Salam Iriqat, et al.
Biomedicines|February 25, 2023
Ocular Behçet Disease-Clinical Manifestations, Treatments and Outcomes According to Age at Disease OnsetMichael Ostrovsky, Amir Rosenblatt, Salam Iriqat, et al.
Ophthalmology|February 13, 2018
Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL IIIEric B Suhler, Alfredo Adán, Antoine P Brézin, et al.
Ophthalmology|November 6, 2020
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or PanuveitisEric B Suhler, Glenn J Jaffe, Eric Fortin, et al.
Ocular Immunology and Inflammation|May 19, 2021
Consensus Recommendations for the Diagnosis of Vitreoretinal LymphomaDenise Carbonell, Sarakshi Mahajan, Soon-Phaik Chee, et al.
Journal for Immunotherapy of Cancer|April 8, 2025
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitorsEileen L Chang, Renee Liu, Kiandokht Keyhanian, et al.
Ocular Immunology and Inflammation|April 7, 2020
The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting ProceedingsRupesh Agrawal, Ilaria Testi, Sarakshi Mahajan, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The British Journal of Ophthalmology|July 11, 2025
Adalimumab biosimilars have similar efficacy to originator adalimumab when treating non-infectious uveitisOren Tomkins-Netzer, Rachael L Niederer, Radgonde Amer, et al.
Acta Ophthalmologica|March 6, 2018
Cat-scratch disease: ocular manifestations and treatment outcomeZohar Habot-Wilner, Omer Trivizki, Michaella Goldstein, et al.
American Journal of Ophthalmology|October 18, 2025
AI-Driven Optical Coherence Tomography Biomarkers for Choroidal Neovascularization Assessment in Punctate Inner Choroidopathy and Multifocal ChoroiditisLorenzo Ferro Desideri, Mathias Gallardo, Muriel Ott, et al.
Acta Ophthalmologica|February 8, 2023
Retinal vascular occlusions in ocular Behçet disease - a comparative analysisMichael Ostrovsky, Dan Ramon, Salam Iriqat, et al.
Biomedicines|February 25, 2023
Ocular Behçet Disease-Clinical Manifestations, Treatments and Outcomes According to Age at Disease OnsetMichael Ostrovsky, Amir Rosenblatt, Salam Iriqat, et al.
Ophthalmology|February 13, 2018
Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL IIIEric B Suhler, Alfredo Adán, Antoine P Brézin, et al.
Ophthalmology|November 6, 2020
Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or PanuveitisEric B Suhler, Glenn J Jaffe, Eric Fortin, et al.
Ocular Immunology and Inflammation|May 19, 2021
Consensus Recommendations for the Diagnosis of Vitreoretinal LymphomaDenise Carbonell, Sarakshi Mahajan, Soon-Phaik Chee, et al.
Journal for Immunotherapy of Cancer|April 8, 2025
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitorsEileen L Chang, Renee Liu, Kiandokht Keyhanian, et al.
Ocular Immunology and Inflammation|April 7, 2020
The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting ProceedingsRupesh Agrawal, Ilaria Testi, Sarakshi Mahajan, et al.
Pageof 7